Using precision medicine
to improve patient outcomes
PrismRA® introduces precision medicine to the treatment of rheumatoid arthritis for the first time, providing objective, science-based guidance for rheumatoid arthritis (RA) therapy selection. The test leverages RNA expression data to identify patients who are unlikely to adequately respond to TNF inhibitor (TNFi) therapies, a targeted therapy commonly used to treat RA, based on their distinct molecular signatures.
The PrismRA test analyzes 23 biological features, including RNA expression data, demographic variables, and disease-associated clinical metrics, that are discriminatory between the molecular signatures of those who respond or do not respond adequately to TNFi therapies.
Identifying molecular signatures indicative of inadequate response
A molecular signature combines a set of biological features to capture an individual’s genetic makeup and disease behavior. These features include RNA, proteins, and other features that reflect a patient’s distinctive disease biology.
Targeted therapies, like TNFi therapies, target specific disease related proteins. Because a disease affects each patient differently, a targeted therapy may work for some patients but not others. An RA patient may fail to have an adequate response to a TNFi therapy if his or her molecular signature is not sufficiently driven by the TNF-ɑ pathway.
PrismRA combines RNA expression data, demographic variables, and disease-associated clinical metrics to increase a molecular signature’s power to predict if a patient will respond inadequately to a TNFi therapy.